Lionsgate content momentum boosts outlook, but debt and valuation cap upside

B. Riley Securities initiated Lionsgate Studios (LION) coverage with a Neutral rating and a $17 price target, noting its strong film slate and improving TV outlook should drive meaningful earnings growth over the next several years. The firm highlights Michael’s ~$960M global box office and forecasts TV segment revenue of ~$1.4B–$1.5B annually, but says upside is limited because the stock has already rallied over 130% post–Starz separation and trades around 17x forward adjusted OIBDA. Balance-sheet risk remains a key constraint, with fiscal 2027 starting debt of ~$1.94B and net leverage of 6.1x EBITDA, even as leverage should improve with debt reduction and higher free cash flow.

Analysis

LION now screens less like a valuation story and more like a levered call option on a sustained theatrical recovery. In that structure, incremental operating upside is diluted by the capital structure: until debt comes down materially, most of the economic value accrues to lenders and any equity rerating is vulnerable to a small miss in slate timing or box-office conversion.

The important mechanism is not one hit film, but the duration of cash generation across the next 4-6 quarters. If the recovery in theatrical output and TV deliveries translates into cleaner free cash flow, the stock can stay bid; if not, the current multiple leaves little margin for error and a credit-driven de-rate becomes the bigger risk than a content miss. The market is also likely underestimating how sensitive the stock is to refinancing terms and spread levels, not just EBITDA.

Contrarian take: the consensus is treating library value and franchise optionality as durable equity value, but in a highly levered studio that value is often monetized first by an acquirer or the debt stack. The cleaner way to express the same box-office thesis is via less levered beneficiaries; LION’s upside is more binary because it is already priced like a recovery is underway. A takeover bid can still squeeze higher, but absent that, the setup looks capped rather than cheap.

Key Decisions for Investors

• Avoid initiating a fresh long in LION at current levels; if already owned, trim into strength and treat the position as a 3-6 month event trade, with the thesis invalidated if leverage does not improve toward <5.5x EBITDA over the next 2-3 quarters.
• Pair trade: long IMAX / short LION for the next 1-2 quarters to isolate the box-office recovery while sidestepping LION’s balance-sheet risk; this should outperform if theatrical attendance improves but credit markets stay tight.
• If maintaining exposure to LION’s M&A optionality, use 6-9 month call spreads instead of common stock to cap downside from a failed deleveraging path while retaining takeover upside.
• Watch quarterly free cash flow conversion and any refinancing/asset-sale announcement; if credit spreads widen or debt paydown stalls, cut the thesis quickly rather than waiting for earnings confirmation.